Your Catalyst to a Lucrative Business
Doxorubicin Market Share, Size, Key Players, Outlook and
Forecasts to 2024 | Hexa Research
“ The enterprise mobility management market is expected to grow at a CAGR
of 27% over the forecast period from 2016 to 2024.”
08 March 2019
Doxorubicin is an anti-cancer chemotherapy drug. It is an intravenous injection through a central or
peripheral venous line. No pill form of this drug is available in the market. Doxorubicin market is expected to
witness a significant growth in the developed regions due to the multiple incidences of cancer occurrence in
these regions. According to World Health Organization (WHO) , in 2012, 14.1 million new cancer cases were
detected worldwide.
Doxorubicin is an anthracycline chemotherapy drug that slows down the growth of cancer cells which is one
of the primary reasons of its demand globally. Four most common cancers worldwide are lung cancer,
prostate cancer, female breast and bowel. Doxorubicin drug provides chemotherapy treatment for all four
cancers which is anticipated to drive the industry in next eight years. Early diagnosis led to the longer
duration of treatment which in turn increases the demand for doxorubicin drug. Increasing effect iveness of
drug therapies are contributing to the higher spending on drugs for cancer care. Moreover, various
government initiatives for controlling cancer and increasing its awareness through governmental
organizations such as Cancer Prevention And Control Research Network (CPCRN )and National Cancer
Institute is creating to have a positive impact on the anti-cancer drug. Increased alcohol consumption, usage
of tobacco coupled with lack of physical activity and unhealthy diet are considered to be main ris k factors of
cancer worldwide. According to WHO estimates, the mortality rate worldwide was 8.2 billion in 2012 and is
expected to rise by about 70% in the near future. Due to aforementioned reasons, anti -cancer drug market
revenues are anticipated to increase in the near future.
Follow Us: